Evidence map›Paper›PMID 32536690›Full record

ArticleBritish journal of cancer2020

Examining treatment responses of diagnostic marrow in murine xenografts to predict relapse in children with acute lymphoblastic leukaemia.

Abdulmohsen M Alruwetei, Katerina Bendak, Babasaheb D Yadav, Hernan Carol, Kathryn Evans, Chelsea Mayoh, Rosemary Sutton, Glenn M Marshall, Richard B Lock

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Abdulmohsen M Alruwetei *Children's Cancer Institute, School of Women's and Children's Health, UNSW Sydney, Sydney, NSW, Australia.
Katerina Bendak *Children's Cancer Institute, School of Women's and Children's Health, UNSW Sydney, Sydney, NSW, Australia.
Babasaheb D YadavChildren's Cancer Institute, School of Women's and Children's Health, UNSW Sydney, Sydney, NSW, Australia.
Hernan CarolChildren's Cancer Institute, School of Women's and Children's Health, UNSW Sydney, Sydney, NSW, Australia.
Kathryn EvansChildren's Cancer Institute, School of Women's and Children's Health, UNSW Sydney, Sydney, NSW, Australia.
Chelsea MayohChildren's Cancer Institute, School of Women's and Children's Health, UNSW Sydney, Sydney, NSW, Australia.
Rosemary SuttonChildren's Cancer Institute, School of Women's and Children's Health, UNSW Sydney, Sydney, NSW, Australia.
Glenn M MarshallChildren's Cancer Institute, School of Women's and Children's Health, UNSW Sydney, Sydney, NSW, Australia.
Richard B LockChildren's Cancer Institute, School of Women's and Children's Health, UNSW Sydney, Sydney, NSW, Australia. rlock@ccia.unsw.edu.au.ORCID http://orcid.org/0000-0002-3436-9071
UNSW Sydney · AUQassim University · SA

Funding

Department of Health | National Health and Medical Research Council (NHMRC) APP1024232Department of Health | National Health and Medical Research Council (NHMRC) APP1059804Department of Health | National Health and Medical Research Council (NHMRC) APP1157871
6 · The paper itself

Abstract

backgroundWhile current chemotherapy has increased cure rates for children with acute lymphoblastic leukaemia (ALL), the largest number of relapsing patients are still stratified as medium risk (MR) at diagnosis (50-60%). This highlights an opportunity to develop improved relapse-prediction models for MR patients. We hypothesised that bone marrow from MR patients who eventually relapsed would regrow faster in a patient-derived xenograft (PDX) model after induction chemotherapy than samples from patients in long-term remission.

methodsDiagnostic bone marrow aspirates from 30 paediatric MR-ALL patients (19 who relapsed, 11 who experienced remission) were inoculated into immune-deficient (NSG) mice and subsequently treated with either control or an induction-type regimen of vincristine, dexamethasone, and L-asparaginase (VXL). Engraftment was monitored by enumeration of the proportion of human CD45

resultsThe TT25% value significantly predicted MR patient relapse. Mutational profiles of PDXs matched their tumours of origin, with a clonal shift towards relapse observed in one set of VXL-treated PDXs.

conclusionsIn conclusion, establishing PDXs at diagnosis and subsequently applying chemotherapy has the potential to improve relapse prediction in paediatric MR-ALL.

Indexed as

AdolescentAnimalsAntineoplastic Combined Chemotherapy ProtocolsAsparaginaseBone MarrowChildChild, PreschoolDexamethasoneFemaleHeterograftsHumansMaleMiceMice, Inbred NODMice, SCIDPrecursor Cell Lymphoblastic Leukemia-LymphomaAsparaginaseDexamethasoneVincristine

Identifiers

PMID32536690
PMCPMC7462974
OpenAlexW3034191415

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.